SciELO - Scientific Electronic Library Online

vol.34 número6Enfermedad cerebrovascular isquémica en pacientes con virus de la inmunodeficiencia humana, un evento de importancia clínicaEnfermedad de Chagas (tripanosomiasis americana) índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados




Links relacionados

  • No hay artículos similaresSimilares en SciELO


Medicina interna de México

versión impresa ISSN 0186-4866


ALARCON-SOTELO, Alejandra et al. Up-to-date in the long-term pharmacological treatment of obesity. A therapeutic option?. Med. interna Méx. [online]. 2018, vol.34, n.6, pp.946-958. ISSN 0186-4866.

Obesity is a chronic disease, with systemic affection and of multifactorial character that constitutes a serious problem of public health, being considered by the World Health Organization a global epidemic. Obesity is the result of a positive energy balance by a long time, where the energy derived from food exceeds the energy expended in everyday life. In order to put an end to this public health problem, treatment options have been sought, although the modifications to the lifestyle included diet and exercise are still the cornerstone of the treatment for obesity, these modifications have not allowed to maintain long-term results; for this reason anti-obesity drugs become a viable option. There are five drugs approved by the FDA nowadays for the long-term treatment of obesity: orlistat, phentermine/topiramate prolonged release, lorcarserin, naltrexone/bupropion prolonged release, and liraglutide, which have shown efficacy and the necessary safety to be taken into account as a therapeutic option. In this article we will review the effectiveness and safety of each of the approved anti-obesity drugs that are available.

Palabras llave : Obesity; Overweight; Antiobesity drugs; Weight loss.

        · resumen en Español     · texto en Español     · Español ( pdf )